Page last updated: 2024-12-07
allotrap
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
allotrap: RN refers to Allotrap 07; small synthetic peptides derived from the alpha1 helix of the heavy chain of HLA class I proteins; inhibits human T cell responses in vitro; prolongs allograft survival in rats and mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 132929 |
MeSH ID | M0243830 |
Synonyms (8)
Synonym |
---|
151232-75-6 |
l-tyrosine, n-(n-(n(2)-(n-(n(2)-(n(2)-(n-(n-(n-l-arginyl-l-alpha-glutamyl)-l-seryl)-l-leucyl)-l-arginyl)-l-asparaginyl)-l-leucyl)-l-arginyl)glycyl)- |
peptide bc-1nl |
allotrap |
DTXSID50164742 |
(2s,8s,11s,14s,17s,20s,23s,26s)-14-(2-amino-2-oxoethyl)-26-((s)-2-amino-5-guanidinopentanamido)-8,17-bis(3-guanidinopropyl)-2-(4-hydroxybenzyl)-23-(hydroxymethyl)-11,20-diisobutyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazanonacosanedioic a |
PD161705 |
AKOS040746539 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Oral administration of RDP58 significantly decreased the incidence of diarrhea and improved the survival rates of mice treated with toxic doses of CPT-11 or 5-fluorouracil." | ( Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Belmar, N; Buelow, R; Fong, T; Huang, L; Zhao, J, 2004) | 0.32 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" In addition, the data suggest that the D2702 isomer is more potent than the L-isomer in vivo and may allow reduced dosage or frequency of administration." | ( Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice. Buelow, R; Gao, L; Woo, J, 1996) | 0.6 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (29)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (31.03) | 18.2507 |
2000's | 19 (65.52) | 29.6817 |
2010's | 1 (3.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 10.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.96) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (10.34%) | 5.53% |
Reviews | 4 (13.79%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 22 (75.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |